WithdrawnPHASE1, PHASE2NCT02344810
C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer
Studying Adenocarcinoma of the oesophagus and oesophagogastric junction
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Eastern Cooperative Oncology Group
- Principal Investigator
- Lakshmi Rajdev, MDECOG-ACRIN Cancer Research Group
- Intervention
- c-Met inhibitor AMG 337(drug)
- Eligibility
- 18 years · All sexes
- Timeline
- 2015
Study locations (1)
- ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States
Collaborators
National Cancer Institute (NCI) · ECOG-ACRIN Cancer Research Group
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02344810 on ClinicalTrials.govOther trials for Adenocarcinoma of the oesophagus and oesophagogastric junction
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07432295Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)I-Mab Biopharma US Limited
- RECRUITINGPHASE1NCT07059299A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric AdenocarcinomaInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- RECRUITINGPHASE1NCT07284186First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid TumorsPlexium, Inc.
- RECRUITINGPHASE2NCT06161818Total Neoadjuvant Therapy for Lymph Node-positive Adenocarcinoma of the OESophagus and Oesophagogastric JunctionErasmus Medical Center
- RECRUITINGPHASE2NCT06628310A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal AdenocarcinomaAbbVie
- RECRUITINGPHASE2NCT05563766A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal CancerVA Office of Research and Development
- RECRUITINGNANCT06649474Evaluation, in Humans, of the Correlation Between Hepatotoxicity, Neurotoxicity Induced by Oxaliplatin, and Blood Levels of HMGB1University Hospital, Clermont-Ferrand
- RECRUITINGPHASE1, PHASE2NCT06445972Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)Merck Sharp & Dohme LLC
See all trials for Adenocarcinoma of the oesophagus and oesophagogastric junction →